Observe Intently (2)pentobarbital will decrease the extent or outcome of suvorexant by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Strong CYP3A4 inducers may well lessen suvorexant efficacy; if amplified suvorexant dose expected, do not exceed twenty mg/daypentobarbital will minimize the extent or outcome of disopyra